Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 12.3% – Still a Buy?

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s share price shot up 12.3% on Thursday . The company traded as high as $5.66 and last traded at $5.65. 3,831,322 shares were traded during trading, a decline of 46% from the average session volume of 7,128,467 shares. The stock had previously closed at $5.03.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CATX shares. UBS Group reiterated a “buy” rating and issued a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. B. Riley Financial cut their target price on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $11.50.

Perspective Therapeutics Stock Up 12.3%

The stock has a 50 day simple moving average of $3.36 and a two-hundred day simple moving average of $3.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its position in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the period. SG Americas Securities LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $46,000. Ground Swell Capital LLC purchased a new position in Perspective Therapeutics during the second quarter worth about $56,000. Los Angeles Capital Management LLC purchased a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $61,000. Finally, Mercer Global Advisors Inc. ADV boosted its position in shares of Perspective Therapeutics by 81.8% during the third quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock worth $100,000 after buying an additional 13,168 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.